ABT-072, also known as potassium trihydrate, is a highly effective non-nucleoside inhibitor of the HCV NS5B polymerase, administered orally. This compound exhibits potent activity against HCV GT1a (with an EC50 of 1 nM) and HCV GT1b (with an EC50 of 0.3 nM).

ABT-072 (potassium trihydrate) is a non-nucleoside inhibitor of the NS5B polymerase, demonstrating nanomolar potency in vitro against genotype 1a and 1b hepatitis C virus polymerases[1].

ABT-072, administered intravenously or orally at dosages of 5 and/or 30 mg/kg (potassium trihydrate), exhibited favorable pharmacokinetic (PK) properties in rats, with outcomes indicating good PK characteristics. Similarly, at dosages of 2.5 and/or 30 mg/kg (potassium trihydrate), ABT-072 showed low plasma clearance and high oral bioavailability in dogs. These results, from pharmacokinetic analyses, highlight ABT-072's potential, suggesting it has efficient systemic absorption and retention, with varying impacts observed across different animal models (rats and dogs).